Instil Bio, Inc.·3

Mar 18, 8:49 PM ET

Vivo Capital Fund IX, L.P. 3

3 · Instil Bio, Inc. · Filed Mar 18, 2021

Insider Transaction Report

Form 3
Period: 2021-03-18
Holdings
  • Series B Preferred Stock

    Common Stock (11,709,696 underlying)
  • Series C Preferred Stock

    Common Stock (477,091 underlying)
Footnotes (2)
  • [F1]Each share of Series B Preferred Stock and Series C Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a one for one basis, has no expiration date and is expected to automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
  • [F2]The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. As the managing members of Capital IX, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Fund IX, but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.

Documents

1 file
  • 3
    doc3.xmlPrimary

    FORM 3 SUBMISSION